Propeller Health, which provides a digital solution for respiratory medicine, and pharma giant GlaxoSmithKline (GSK) are expanding their collaboration, which started in 2015, to prepare for and undertake commercial activities using the Propeller clip-on sensor and software platform for use with GSK’s ELLIPTA Inhaler. Said sensor automatically records medication use, which the Propeller platform analyzes and presents to patients and physicians through its data-driven digital interfaces, providing an in-depth view into adherence.
The two companies will continue ongoing R&D efforts to collect evidence from the Propeller clip-on sensor and software platform used in conjunction with GSK’s respiratory medicines for asthma and COPD.
“We are excited to be working closely with GSK to make the sensor for the ELLIPTA inhaler available in our commercial programs, and for the first time, as part of commercial pilots with GSK outside the US,” David Van Sickle, CEO and co-founder of Propeller, said in a statement. “Companion digital experiences simplify and personalize the management of chronic respiratory disease, and help ensure individuals and their physicians realize the benefits of inhaled medicines.”
The Propeller platform has been used by patients and physicians in over 55 commercial programs across the United States, including major healthcare systems, payers, employers and other commercial partners. It is compatible with the majority of commonly used asthma and COPD inhaler devices including controller and reliever metered dose inhalers (MDIs), and other inhaler devices — including dry powder inhalers (DPIs) and soft mist inhalers (SMIs).
This latest announcement comes on the heels of recent successful CE marking and US FDA 510(k) class II clearance of the Propeller sensor and software program for the ELLIPTA Inhaler, in late 2016.